Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says

A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.  

Boxing ropes
Intercept may struggle to explain why Ocaliva should convert to regular approval. • Source: Shutterstock

Intercept Pharmaceuticals, Inc. may struggle to preserve the future of its primary biliary cholangitis drug Ocaliva (obeticholic acid) following the US Food and Drug Administration’s negative review of a confirmatory trial and real-world evidence study.

Intercept Pharmaceuticals, Inc., a wholly owned subsidiary of Alfasigma S.p.A

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA Performance Tracker

More from Regulatory Trackers